Dramatic, significant metabolic response to a one‐time pembrolizumab treatment following a relapse of pre‐existing organizing pneumonia in a patient with advanced non‐small cell lung cancer: A case report

Abstract Immune checkpoint inhibitors can often trigger immune‐related adverse events (irAEs), such as relapse of pre‐existing interstitial pneumonia. Here, we report the case of an 88‐year‐Japanese man diagnosed with advanced lung adenocarcinoma with a high tumor proportion score of programmed deat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Motoyasu Kato, Mikiko Mori, Keita Miura, Tetsuhiko Asao, Hiroaki Motomura, Koichi Nishino, Ryo Ko, Ryo Koyama, Takuo Hayashi, Kazuhisa Takahashi
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	drug‐induced interstitial pneumonia immune checkpoint inhibitors immune‐related adverse event non‐small cell lung carcinoma pembrolizumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/16663f7f5c7349c497012a0c4953698f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:16663f7f5c7349c497012a0c4953698f
record_format	dspace
spelling	oai:doaj.org-article:16663f7f5c7349c497012a0c4953698f2021-11-14T23:28:26ZDramatic, significant metabolic response to a one‐time pembrolizumab treatment following a relapse of pre‐existing organizing pneumonia in a patient with advanced non‐small cell lung cancer: A case report1759-77141759-770610.1111/1759-7714.14185https://doaj.org/article/16663f7f5c7349c497012a0c4953698f2021-11-01T00:00:00Zhttps://doi.org/10.1111/1759-7714.14185https://doaj.org/toc/1759-7706https://doaj.org/toc/1759-7714Abstract Immune checkpoint inhibitors can often trigger immune‐related adverse events (irAEs), such as relapse of pre‐existing interstitial pneumonia. Here, we report the case of an 88‐year‐Japanese man diagnosed with advanced lung adenocarcinoma with a high tumor proportion score of programmed death‐ligand 1. Six years earlier, he had developed organizing pneumonia (OP), a subtype of interstitial pneumonia, that was treated with steroid pulse therapy maintained with prolonged prednisolone administration. We initiated pembrolizumab as the first‐line treatment. One month after the first pembrolizumab administration, high resolution computed tomography (HRCT) of the chest demonstrated ground‐glass opacities and consolidations. We suspected pembrolizumab‐induced OP relapse, an irAE. His oxygenation was normal; therefore, we discontinued pembrolizumab without additional treatment for OP relapse. Four months after OP relapse, HRCT showed no new findings. After significant amelioration of OP, although the size of the tumor shadow remained the same on HRCT, positron emission tomography‐computed tomography demonstrated the disappearance of the standardized uptake value of the primary tumor, mediastinal lymph nodes, and pleural nodules. In conclusion, this is the first report of a dramatic, significant metabolic response after a single pembrolizumab treatment despite the relapse of pre‐existing OP in a patient with advanced lung adenocarcinoma.Motoyasu KatoMikiko MoriKeita MiuraTetsuhiko AsaoHiroaki MotomuraKoichi NishinoRyo KoRyo KoyamaTakuo HayashiKazuhisa TakahashiWileyarticledrug‐induced interstitial pneumoniaimmune checkpoint inhibitorsimmune‐related adverse eventnon‐small cell lung carcinomapembrolizumabNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENThoracic Cancer, Vol 12, Iss 22, Pp 3076-3079 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	drug‐induced interstitial pneumonia immune checkpoint inhibitors immune‐related adverse event non‐small cell lung carcinoma pembrolizumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	drug‐induced interstitial pneumonia immune checkpoint inhibitors immune‐related adverse event non‐small cell lung carcinoma pembrolizumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Motoyasu Kato Mikiko Mori Keita Miura Tetsuhiko Asao Hiroaki Motomura Koichi Nishino Ryo Ko Ryo Koyama Takuo Hayashi Kazuhisa Takahashi Dramatic, significant metabolic response to a one‐time pembrolizumab treatment following a relapse of pre‐existing organizing pneumonia in a patient with advanced non‐small cell lung cancer: A case report
description	Abstract Immune checkpoint inhibitors can often trigger immune‐related adverse events (irAEs), such as relapse of pre‐existing interstitial pneumonia. Here, we report the case of an 88‐year‐Japanese man diagnosed with advanced lung adenocarcinoma with a high tumor proportion score of programmed death‐ligand 1. Six years earlier, he had developed organizing pneumonia (OP), a subtype of interstitial pneumonia, that was treated with steroid pulse therapy maintained with prolonged prednisolone administration. We initiated pembrolizumab as the first‐line treatment. One month after the first pembrolizumab administration, high resolution computed tomography (HRCT) of the chest demonstrated ground‐glass opacities and consolidations. We suspected pembrolizumab‐induced OP relapse, an irAE. His oxygenation was normal; therefore, we discontinued pembrolizumab without additional treatment for OP relapse. Four months after OP relapse, HRCT showed no new findings. After significant amelioration of OP, although the size of the tumor shadow remained the same on HRCT, positron emission tomography‐computed tomography demonstrated the disappearance of the standardized uptake value of the primary tumor, mediastinal lymph nodes, and pleural nodules. In conclusion, this is the first report of a dramatic, significant metabolic response after a single pembrolizumab treatment despite the relapse of pre‐existing OP in a patient with advanced lung adenocarcinoma.
format	article
author	Motoyasu Kato Mikiko Mori Keita Miura Tetsuhiko Asao Hiroaki Motomura Koichi Nishino Ryo Ko Ryo Koyama Takuo Hayashi Kazuhisa Takahashi
author_facet	Motoyasu Kato Mikiko Mori Keita Miura Tetsuhiko Asao Hiroaki Motomura Koichi Nishino Ryo Ko Ryo Koyama Takuo Hayashi Kazuhisa Takahashi
author_sort	Motoyasu Kato
title	Dramatic, significant metabolic response to a one‐time pembrolizumab treatment following a relapse of pre‐existing organizing pneumonia in a patient with advanced non‐small cell lung cancer: A case report
title_short	Dramatic, significant metabolic response to a one‐time pembrolizumab treatment following a relapse of pre‐existing organizing pneumonia in a patient with advanced non‐small cell lung cancer: A case report
title_full	Dramatic, significant metabolic response to a one‐time pembrolizumab treatment following a relapse of pre‐existing organizing pneumonia in a patient with advanced non‐small cell lung cancer: A case report
title_fullStr	Dramatic, significant metabolic response to a one‐time pembrolizumab treatment following a relapse of pre‐existing organizing pneumonia in a patient with advanced non‐small cell lung cancer: A case report
title_full_unstemmed	Dramatic, significant metabolic response to a one‐time pembrolizumab treatment following a relapse of pre‐existing organizing pneumonia in a patient with advanced non‐small cell lung cancer: A case report
title_sort	dramatic, significant metabolic response to a one‐time pembrolizumab treatment following a relapse of pre‐existing organizing pneumonia in a patient with advanced non‐small cell lung cancer: a case report
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/16663f7f5c7349c497012a0c4953698f
work_keys_str_mv	AT motoyasukato dramaticsignificantmetabolicresponsetoaonetimepembrolizumabtreatmentfollowingarelapseofpreexistingorganizingpneumoniainapatientwithadvancednonsmallcelllungcanceracasereport AT mikikomori dramaticsignificantmetabolicresponsetoaonetimepembrolizumabtreatmentfollowingarelapseofpreexistingorganizingpneumoniainapatientwithadvancednonsmallcelllungcanceracasereport AT keitamiura dramaticsignificantmetabolicresponsetoaonetimepembrolizumabtreatmentfollowingarelapseofpreexistingorganizingpneumoniainapatientwithadvancednonsmallcelllungcanceracasereport AT tetsuhikoasao dramaticsignificantmetabolicresponsetoaonetimepembrolizumabtreatmentfollowingarelapseofpreexistingorganizingpneumoniainapatientwithadvancednonsmallcelllungcanceracasereport AT hiroakimotomura dramaticsignificantmetabolicresponsetoaonetimepembrolizumabtreatmentfollowingarelapseofpreexistingorganizingpneumoniainapatientwithadvancednonsmallcelllungcanceracasereport AT koichinishino dramaticsignificantmetabolicresponsetoaonetimepembrolizumabtreatmentfollowingarelapseofpreexistingorganizingpneumoniainapatientwithadvancednonsmallcelllungcanceracasereport AT ryoko dramaticsignificantmetabolicresponsetoaonetimepembrolizumabtreatmentfollowingarelapseofpreexistingorganizingpneumoniainapatientwithadvancednonsmallcelllungcanceracasereport AT ryokoyama dramaticsignificantmetabolicresponsetoaonetimepembrolizumabtreatmentfollowingarelapseofpreexistingorganizingpneumoniainapatientwithadvancednonsmallcelllungcanceracasereport AT takuohayashi dramaticsignificantmetabolicresponsetoaonetimepembrolizumabtreatmentfollowingarelapseofpreexistingorganizingpneumoniainapatientwithadvancednonsmallcelllungcanceracasereport AT kazuhisatakahashi dramaticsignificantmetabolicresponsetoaonetimepembrolizumabtreatmentfollowingarelapseofpreexistingorganizingpneumoniainapatientwithadvancednonsmallcelllungcanceracasereport
_version_	1718428967565787136

Dramatic, significant metabolic response to a one‐time pembrolizumab treatment following a relapse of pre‐existing organizing pneumonia in a patient with advanced non‐small cell lung cancer: A case report

Ejemplares similares